Preclinical Efficacy and Mechanisms of Mesenchymal Stem Cells in Animal Models of Autoimmune Diseases.
- Author:
Hong Kyung LEE
1
;
Sang Hee LIM
;
In Sung CHUNG
;
Yunsoo PARK
;
Mi Jeong PARK
;
Ju Young KIM
;
Yong Guk KIM
;
Jin Tae HONG
;
Youngsoo KIM
;
Sang Bae HAN
Author Information
- Publication Type:In Vitro ; Review
- Keywords: Mesenchymal stem cells; Immunoregulation; Autoimmune diseases
- MeSH: Adipose Tissue; Arthritis, Rheumatoid; Autoimmune Diseases*; B-Lymphocytes; Bone Marrow; Crohn Disease; Dendritic Cells; Dinoprostone; Encephalomyelitis, Autoimmune, Experimental; Heme Oxygenase-1; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-10; Leukocytes; Lupus Erythematosus, Systemic; Mesenchymal Stromal Cells*; Models, Animal*; Nitric Oxide; Placenta; Stem Cells; T-Lymphocytes; T-Lymphocytes, Regulatory; Umbilical Cord
- From:Immune Network 2014;14(2):81-88
- CountryRepublic of Korea
- Language:English
- Abstract: Mesenchymal stem cells (MSCs) are present in diverse tissues and organs, including bone marrow, umbilical cord, adipose tissue, and placenta. MSCs can expand easily in vitro and have regenerative stem cell properties and potent immunoregulatory activity. They inhibit the functions of dendritic cells, B cells, and T cells, but enhance those of regulatory T cells by producing immunoregulatory molecules such as transforming growth factor-beta, hepatic growth factors, prostaglandin E2, interleukin-10, indolamine 2,3-dioxygenase, nitric oxide, heme oxygenase-1, and human leukocyte antigen-G. These properties make MSCs promising therapeutic candidates for the treatment of autoimmune diseases. Here, we review the preclinical studies of MSCs in animal models for systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, and experimental autoimmune encephalomyelitis, and summarize the underlying immunoregulatory mechanisms.
